Basic Information
EMA regulatory identification and product classification information
EMA Identifiers
Overview Summary
Comprehensive product overview and regulatory summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Active Substances (1)
repaglinide
Documents (9)
Repaglinide Krka : EPAR - Public assessment report
November 15, 2009
INITIAL_MARKETING_AUTHORISATION_DOCUMENTS
Committee for medicinal products for human use, summary of positive opinion for Repaglinide Krka
July 22, 2009
INITIAL_MARKETING_AUTHORISATION_DOCUMENTS
Repaglinide Krka : EPAR - Procedural steps taken and scientific information after authorisation (archive)
August 15, 2012
CHANGES_SINCE_INITIAL_AUTHORISATION
Repaglinide Krka : EPAR - Public assessment report
November 15, 2009
CHANGES_SINCE_INITIAL_AUTHORISATION
Committee for medicinal products for human use, summary of positive opinion for Repaglinide Krka
July 22, 2009
CHANGES_SINCE_INITIAL_AUTHORISATION
Repaglinide Krka : EPAR - Product Information
November 15, 2009
DRUG_PRODUCT_INFORMATION
Repaglinide Krka : EPAR - Procedural steps taken and scientific information after authorisation
February 4, 2025
CHANGES_SINCE_INITIAL_AUTHORISATION
Repaglinide Krka : EPAR - All Authorised presentations
November 15, 2009
AUTHORISED_PRESENTATIONS
Repaglinide Krka : EPAR - Summary for the public
November 15, 2009
OVERVIEW_DOCUMENT
Overview Q&A (8)
Question
Other information about Repaglinide Krka
Answer
The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Krka to Krka, d.d., Novo mesto on 4 November 2009.
Question
How is Repaglinide Krka used?
Answer
Repaglinide Krka is taken before meals, normally up to 15 minutes before each main meal. The dose is adjusted to give the best control. A doctor should regularly test the patient’s blood glucose to find the lowest effective dose. Repaglinide Krka can also be used for type-2-diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
The recommended starting dose is 0.5 mg. This dose may need to be increased after one or two weeks.
If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Repaglinide Krka is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Question
How does Repaglinide Krka work?
Answer
Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Repaglinide Krka helps the pancreas to produce more insulin at mealtimes and is used to control type-2 diabetes.
Question
What is Repaglinide Krka?
Answer
Repaglinide Krka is a medicine that contains the active substance repaglinide. It is available as round tablets (white: 0.5 mg; yellow: 1 mg; pink: 2 mg).
Repaglinide Krka is a ‘generic medicine’. This means that Repaglinide Krka is similar to a ‘reference medicine’ already authorised in the European Union (EU) called NovoNorm.
Question
What is Repaglinide Krka used for?
Answer
Repaglinide Krka is used in patients who have type-2 diabetes (non-insulin-dependent diabetes). It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
The medicine can only be obtained with a prescription.
Question
How has Repaglinide Krka been studied?
Answer
Because Repaglinide Krka is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
Question
What are the benefit and risk of Repaglinide Krka?
Answer
Because Repaglinide Krka is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Question
Why has Repaglinide Krka been approved?
Answer
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Krka has been shown to have comparable quality and to be bioequivalent to NovoNorm. Therefore, the CHMP’s view was that, as for NovoNorm, the benefit outweighs the identified risk. The Committee recommended that Repaglinide Krka be given marketing authorisation.